Completed PHASE1 INTERVENTIONAL 5-arm NCT00982826

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Doses (7 Days) of ABT-072 and an Open-label Study to Evaluate the Effect of Food on the Pharmacokinetic

Sponsor: Abbott

Conditions Hepatitis C

Interventions ABT-072 Placebo

Updated 6 times since 2017 Last updated: Oct 19, 2010 Started: Sep 30, 2009 Primary completion: Dec 31, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00982826, this PHASE1 trial focuses on Hepatitis C and remains completed. Sponsored by Abbott, it has been updated 6 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Waukegan, United States